These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38461410)
1. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia. Sun Y; Wang X; Chen WM; Hao Y; Li LD; Li JY; Sun K; Shi ZY; Jiang H; Jiang Q; Huang XJ; Qin YZ Hematol Oncol; 2024 Mar; 42(2):e3264. PubMed ID: 38461410 [TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia]. Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444 [No Abstract] [Full Text] [Related]
3. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825 [TBL] [Abstract][Full Text] [Related]
4. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815 [TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Rücker FG; Agrawal M; Corbacioglu A; Weber D; Kapp-Schwoerer S; Gaidzik VI; Jahn N; Schroeder T; Wattad M; Lübbert M; Koller E; Kindler T; Götze K; Ringhoffer M; Westermann J; Fiedler W; Horst HA; Greil R; Schroers R; Mayer K; Heinicke T; Krauter J; Schlenk RF; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Döhner K Blood; 2019 Nov; 134(19):1608-1618. PubMed ID: 31554635 [TBL] [Abstract][Full Text] [Related]
7. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309 [TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia. Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618 [TBL] [Abstract][Full Text] [Related]
11. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Wang Y; Wu DP; Liu QF; Qin YZ; Wang JB; Xu LP; Liu YR; Zhu HH; Chen J; Dai M; Huang XJ Blood; 2014 Sep; 124(12):1880-6. PubMed ID: 25082877 [TBL] [Abstract][Full Text] [Related]
12. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts. Sasaki K; Tsujimoto S; Miyake M; Uchiyama Y; Ikeda J; Yoshitomi M; Shimosato Y; Tokumasu M; Matsuo H; Yoshida K; Ohki K; Kaburagi T; Yamato G; Hara Y; Takeuchi M; Kinoshita A; Tomizawa D; Taga T; Adachi S; Tawa A; Horibe K; Hayashi Y; Matsumoto N; Ito S; Shiba N Br J Haematol; 2021 Jul; 194(2):414-422. PubMed ID: 34120331 [TBL] [Abstract][Full Text] [Related]
13. [Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations]. Han SY; Zhou HX; Han Y; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2024 Aug; 45(8):767-771. PubMed ID: 39307724 [No Abstract] [Full Text] [Related]
14. [The prognostic value of cloned genetic mutations detected by second-generation sequencing in RUNX1-RUNX1T1 positive acute myeloid leukemia patients receiving intensive consolidation therapy]. Yu JQ; Xue SL; Li Z; Wang J; Wang C; Chu XL; Han R; Tao T; Qiu QC; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):210-215. PubMed ID: 32311890 [No Abstract] [Full Text] [Related]
15. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771 [TBL] [Abstract][Full Text] [Related]
16. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1. Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443 [TBL] [Abstract][Full Text] [Related]
17. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164 [TBL] [Abstract][Full Text] [Related]
18. Machine learning derived genomics driven prognostication for acute myeloid leukemia with Shaikh AF; Kakirde C; Dhamne C; Bhanshe P; Joshi S; Chaudhary S; Chatterjee G; Tembhare P; Prasad M; Roy Moulik N; Gokarn A; Bonda A; Nayak L; Punatkar S; Jain H; Bagal B; Shetty D; Sengar M; Narula G; Khattry N; Banavali S; Gujral S; P G S; Patkar N Leuk Lymphoma; 2020 Dec; 61(13):3154-3160. PubMed ID: 32757686 [TBL] [Abstract][Full Text] [Related]
19. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients. Park SH; Chi HS; Cho YU; Jang S; Park CJ Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260 [TBL] [Abstract][Full Text] [Related]
20. Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. Qin YZ; Wang Y; Xu LP; Zhang XH; Zhao XS; Liu KY; Huang XJ J Mol Diagn; 2020 Feb; 22(2):188-195. PubMed ID: 31751675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]